Aperio VERSA - Visikol's Highly Multiplexed Immunohistochemistry Approach to Drug Discovery

Visikol is a biotechnology company focused on advanced imaging, digital pathology and 3D cell culture assays that has developed a unique imaging platform that allows for 10+ plex immunofluorescent slide imaging. Through this presentation, Visikol will provide a background on various multiplex tissue imaging approaches and will describe how they can be used to answer complex research questions such as surveying the immune cell population within a tumor microenvironment or evaluating therapeutics for infectious diseases. Specifically, Visikol will discuss how its proprietary multiplex approach has been leveraged through a partnership with Hackensack Meridian Health (HMH) to evaluate tuberculosis treatments. This work is funded by the Bill & Melinda Gates Foundation using Visikol's multiplex approach combined with several other imaging modalities to evaluate treatments using a multi-modal imaging approach.

 

Learning Objectives